Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 130 pages

Showing 101 - 130


kidney cancer

Accumulation of Metabolite Fumarate May Be Linked to Hereditary Leiomyomatosis and Renal Cell Cancer

Researchers funded by the Medical Research Council (MRC) have shown that when the metabolite fumarate accumulates in a hereditary form of renal cancer, it leads to an epigenetic reprogramming that drives cancer, according to a study published by Sciacovelli et al in Nature. The tumor growth...

kidney cancer

Metabolic Gene-Expression Profile May Identify Kidney Cancer Patients Unlikely to Benefit From Nivolumab

Renal cell carcinomas (RCC) positive for the protein programmed death ligand 1 (PD-L1) from patients who did not respond to treatment with the anti–PD-1 therapeutic nivolumab (Opdivo) had significantly higher expression of genes associated with metabolism, compared with PD-L1–positive...

kidney cancer

ASCO 2016: Nivolumab Extends Survival for Patients With Advanced Renal Cell Carcinoma Treated Beyond Disease Progression

In a large randomized study, the immunotherapy drug nivolumab (Opdivo), an anti­­–PD-1 (programmed cell death protein 1) monoclonal antibody, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results ...

kidney cancer

David F. McDermott, MD, and Toni K. Choueiri, MD, on Advanced RCC: Nivolumab in Previously Treated Patients

David F. McDermott, MD, of Beth Israel Deaconess Medical Center, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discuss an update on data from phase I and II studies of nivolumab given to patients with metastatic renal cell carcinoma, including long-term overall survival and...

kidney cancer

FDA Approves Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma

On May 13, 2016, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules (Lenvima), in combination with everolimus (Afinitor) for the treatment of advanced renal cell carcinoma following one prior antiangiogenic therapy. Lenvatinib was first approved in 2015 for the treatment...

kidney cancer

FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy

On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The...

kidney cancer
kidney cancer

Removal of Complex Renal Tumors Performed Safely by Robotic Surgery in Selected Patients

Renal cell carcinoma can sometimes spread to the inferior vena cava, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, reported Abaza...

kidney cancer
kidney cancer

GU Symposium 2016: Cabozantinib Improves Upon the Standard of Care for Advanced Kidney Cancer

New analyses from a phase III clinical trial of patients with previously treated advanced kidney cancer demonstrated that patients of all risk levels experience more benefit from cabozantinib (Cometriq) than from the current standard of care, everolimus (Afinitor). The greater activity of...

kidney cancer

FDA Approves Nivolumab to Treat Advanced Kidney Cancer

The U.S. Food and Drug Administration today approved nivolumab (Opdivo) to treat patients with metastatic renal cell carcinoma who have received a prior antiangiogenic therapy. Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2,...

kidney cancer
lung cancer
skin cancer
lymphoma
kidney cancer
head and neck cancer

Kidney Failure and Its Treatment May Impact Cancer Risk

For patients with kidney failure, poor kidney function and immunosuppressant medications may increase their risk of developing different types of cancer. The findings, which are published by Yanik et al in the Journal of the American Society of Nephrology, suggest the need for persistent cancer...

kidney cancer
issues in oncology

Increased Meat Consumption May Be Linked to Elevated Kidney Cancer Risk

Diets high in meat may lead to an increased risk of developing renal cell carcinoma through intake of carcinogenic compounds created by certain cooking techniques, such as barbecuing and pan-frying. As part of a new study from The University of Texas MD Anderson Cancer Center, published by...

kidney cancer

ECC 2015: Nivolumab Improves Overall Survival in Patients With Advanced Kidney Cancer

The targeted drug nivolumab (Opdivo) significantly prolonged survival in patients with advanced kidney cancer whose disease had progressed after their first treatment, according to the results (Abstract 3LBA) presented at the 2015 European Cancer Congress (ECC) in Vienna, Austria, and published...

kidney cancer

ECC 2015: Cabozantinib Improves Survival in Patients With Advanced Kidney Cancer

Patients with advanced kidney cancer lived for nearly twice as long without their disease progressing if they were treated with cabozantinib (Cometriq), a drug that inhibits the action of tyrosine kinases. Toni Choueiri, MD, presented the research (Abstract 4LBA) at the Presidential Session of the...

kidney cancer

FDA Grants Breakthrough Therapy Designation to Lenvatinib for Metastatic Renal Cell Carcinoma

The U.S. Food and Drug Administration (FDA) granted lenvatinib (Lenvima) Breakthrough Therapy designation for investigational use in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib...

kidney cancer

ASCO 2015: Study Clarifies Best Treatments for Non–Clear Cell Kidney Cancers

A head-to-head comparison of two biologic therapies used to treat a subset of patients with advanced kidney cancers provides much-needed clarity on the preferred method of first-line treatment. The phase II ASPEN trial, led by researchers at the Duke Cancer Institute, is the first and largest trial ...

kidney cancer
issues in oncology

ASCO 2015: Augmenting Standard Therapies Increases Cure Rates for High-Risk Wilms Tumor

Two phase III Children’s Oncology Group studies found that augmenting therapy with additional drugs improved outcomes for children with a high-risk form of Wilms tumor. These patients have a specific chromosomal abnormality associated with a poorer prognosis. In prior research, such patients...

hepatobiliary cancer
lymphoma
prostate cancer
kidney cancer

Cancer Rates Significantly Increased Among Patients With Hepatitis C

Results presented on April 24 at The International Liver Congress 2015 (Abstract O058) in Vienna, Austria, show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV...

kidney cancer
issues in oncology

Study Finds Lycopene May Be Associated With Lower Risk for Kidney Cancer in Postmenopausal Women

A higher intake by postmenopausal women of lycopene, an antioxidant found in foods like tomatoes, watermelon, and papaya, may lower the risk of renal cell carcinoma, a type of kidney cancer. A study describing these findings was published by Ho et al in Cancer. In 2014, 63,920 estimated new cases...

kidney cancer
kidney cancer

Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney Cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant sorafenib (Nexavar) or sunitinib (Sutent). The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery ...

kidney cancer

High-Dose Interleukin-2 Effective in Metastatic Renal Cell Cancer Pretreated With VEGF-Targeted Therapies

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pretreated with VEGF-targeted agents, according to research presented recently at the ESMO Symposium on Immuno-Oncology in Geneva (Abstract 4O). “Despite the wide and increasing range of therapies...

kidney cancer
kidney cancer

Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy

Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...

kidney cancer

New Research Shows Association of Kidney Cancer With Use of Aristolochic Acid

New research by the international Cancer Genomics of the Kidney consortium (CAGEKID) reveals an important connection between kidney cancer and exposure to aristolochic acid, an ingredient in some herbal remedies. The findings, published by Scelo et al in Nature Communications, have important...

kidney cancer
issues in oncology

Genomic Sequencing Reveals Unique Genetic Alterations in Chromophobe Renal Cell Carcinoma

An international scientific collaboration led by Baylor College of Medicine as part of The Cancer Genome Atlas initiative has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer. The study, which describes the landscape of somatic genomic alterations of...

kidney cancer
kidney cancer

Metabolic Enzyme Stops Growth of Most Common Type of Kidney Cancer

In an analysis of metabolites in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth. The new study, published in Nature by Simon et al, demonstrated that an enzyme called FBP1,...

kidney cancer
kidney cancer

Study Confirms Clinical Benefit for Interleukin-2 Immunotherapy in Patients With Advanced Kidney Cancer

A retrospective study published online ahead of print in Urology by researchers at Roswell Park Cancer Institute found that patients with metastatic kidney cancer—even those with chronic renal insufficiency—can tolerate and benefit from high-dose interleukin-2 (HDIL-2) immunotherapy....

skin cancer
kidney cancer

Antibody Could Be Used to Target Tumor-Enhancing Protein, Study Shows

In a phase I study published in PLOS ONE, treating patients with advanced melanoma and kidney cancer with an antibody that targets a tumor-enhancing protein was found to have an acceptable safety profile and showed preliminary evidence of antitumor activity. The findings by Morris et al shed light...

kidney cancer
kidney cancer

Angiotensin System Inhibitors Improve Survival in Hypertensive Patients With Metastatic Renal Cell Carcinoma

According to a retrospective study, the use of angiotensin system inhibitors, such as lisinopril, captopril, and losartan, improved the survival of patients with metastatic renal cell carcinoma by 9 months, compared with patients who were not receiving these types of agents. Survival was even...

solid tumors
kidney cancer

Progression of Renal Cell Carcinoma Linked to Shifts in Tumor Metabolism

Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma. Their findings demonstrate that normal...

kidney cancer

Study Finds Partial Kidney Removal Leads to Greater Survival and Cost Savings for Patients with Kidney Tumors

For patients with kidney tumors, a new study shows the health and economic advantages to removing just the tumor as opposed to the entire kidney. Robotic surgery, including the daVinci Surgical System and Firefly fluorescence imaging that lights up kidney tumors, are among the latest techniques to...

issues in oncology
kidney cancer
kidney cancer
issues in oncology

Trio of Biomarkers May Help Identify Kidney Cancer in Early Stages

A new immunoassay that tests for the presence of three biomarkers appears to be a valid screening method for the early detection of malignant kidney cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research....

Advertisement

Advertisement



Advertisement